On June 30, 2026, AC Immune SA announced 12-month data from the Phase 1b/2 ABATE Trial evaluating ACI-24 for the treatment of Prodromal Alzheimer’s Disease. The company operates in the biotechnology industry and develops immunotherapies for neurodegenerative diseases.
